Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register ; volume:11 ; number:2 ; day:8 ; month:4 ; year:2009 ; pages:1-9 ; date:4.2009
Arthritis Research & Therapy ; 11, Heft 2 (8.4.2009), 1-9, 4.2009
- Beteiligte Personen und Organisationen
-
Saad, Amr A.
Ashcroft, Darren M.
Watson, Kath D.
Hyrich, Kimme L.
Noyce, Peter R.
Symmons, Deborah PM
SpringerLink (Online service)
- DOI
-
10.1186/ar2670
- URN
-
urn:nbn:de:1111-2016050311715
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saad, Amr A.
- Ashcroft, Darren M.
- Watson, Kath D.
- Hyrich, Kimme L.
- Noyce, Peter R.
- Symmons, Deborah PM
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment persistence of biologics among patients with psoriatic arthritis
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Biologics in general medicine : with 23 tables
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Rheumatology
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Biologics in general medicine : with 23 tables
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Rheumatology
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Biologics in general medicine : with 23 tables
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Rheumatology